Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71.
Eisenberger
Mario A
MA
Johns Hopkins University-School of Medicine, Oncology Center, East Baltimore Campus, CRB 1M-Oncology, 1650 Orleans Street, Baltimore, MD 21231-1000, USA. eisenma@jhmi.edu